214 related articles for article (PubMed ID: 16434259)
21. Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
Ferrigno D; Buccheri G;
Lung Cancer; 2004 Sep; 45(3):373-80. PubMed ID: 15301878
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study.
Blanco R; Solé J; Montesinos J; Mesía C; Algara M; Terrassa J; Gay M; Domenech M; Bastus R; Bover I; Nogué M; Vadell C;
Lung Cancer; 2008 Oct; 62(1):62-71. PubMed ID: 18440089
[TBL] [Abstract][Full Text] [Related]
23. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin.
Arrieta O; Gallardo-Rincón D; Villarreal-Garza C; Michel RM; Astorga-Ramos AM; Martínez-Barrera L; de la Garza J
J Thorac Oncol; 2009 Jul; 4(7):845-52. PubMed ID: 19487963
[TBL] [Abstract][Full Text] [Related]
24. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
[TBL] [Abstract][Full Text] [Related]
25. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.
Zinner RG; Komaki R; Cox JD; Glisson BS; Pisters KM; Herbst RS; Kies M; Liao Z; Hong WK; Fossella FV
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):119-27. PubMed ID: 18556142
[TBL] [Abstract][Full Text] [Related]
26. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
[TBL] [Abstract][Full Text] [Related]
27. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso AM; Pegna AL; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte PF; Falcone A;
Lung Cancer; 2005 Apr; 48(1):121-7. PubMed ID: 15777979
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
Anderson H; Hopwood P; Stephens RJ; Thatcher N; Cottier B; Nicholson M; Milroy R; Maughan TS; Falk SJ; Bond MG; Burt PA; Connolly CK; McIllmurray MB; Carmichael J
Br J Cancer; 2000 Aug; 83(4):447-53. PubMed ID: 10945489
[TBL] [Abstract][Full Text] [Related]
29. Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
Neubauer MA; Reynolds CH; Joppert MG; Whitaker T; Ghaddar H; Marsland TA; Asmar L
Clin Lung Cancer; 2005 Jan; 6(4):245-9. PubMed ID: 15694017
[TBL] [Abstract][Full Text] [Related]
30. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
[TBL] [Abstract][Full Text] [Related]
32. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Takada M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Fukuoka M
Cancer Chemother Pharmacol; 1998; 41(3):217-22. PubMed ID: 9443638
[TBL] [Abstract][Full Text] [Related]
33. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
Martoni A; Di Fabio F; Guaraldi M; Piana E; Ramini R; Lelli G; Palomba G; Artioli F; Bandieri E; Robustelli Della Cuna G; Preti P
Am J Clin Oncol; 2001 Dec; 24(6):614-7. PubMed ID: 11801766
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Bepler G; Dilling TJ; Wagner H; Hazelton T; Williams C; Chen DT; Greenberg H; Walsh F; Simon G; Tanvetyanon T; Chiappori A; Haura E; Stevens C
J Thorac Oncol; 2011 Mar; 6(3):553-8. PubMed ID: 21289520
[TBL] [Abstract][Full Text] [Related]
35. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer.
Yang CH; Tsai CM; Wang LS; Lee YC; Chang CJ; Lui LT; Yen SH; Hsu C; Cheng AL; Liu MY; Chiang SC; Chen YM; Luh KT; Huang MH; Yang PC; Perng RP
Br J Cancer; 2002 Jan; 86(2):190-5. PubMed ID: 11870504
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
[TBL] [Abstract][Full Text] [Related]
38. Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Schallier D; Bral S; Ilsen B; Neyns B; Fontaine C; Decoster L; De Mey J; Meysman M; De Grève J
J Thorac Oncol; 2009 Jun; 4(6):728-35. PubMed ID: 19404217
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
